[go: up one dir, main page]

FI964004L - Serotoniiniantagonistien (5HT3) käyttö fibromyalgian hoitoon - Google Patents

Serotoniiniantagonistien (5HT3) käyttö fibromyalgian hoitoon Download PDF

Info

Publication number
FI964004L
FI964004L FI964004A FI964004A FI964004L FI 964004 L FI964004 L FI 964004L FI 964004 A FI964004 A FI 964004A FI 964004 A FI964004 A FI 964004A FI 964004 L FI964004 L FI 964004L
Authority
FI
Finland
Prior art keywords
fibromyalgia
treatment
serotonin antagonists
serotonin
antagonists
Prior art date
Application number
FI964004A
Other languages
English (en)
Swedish (sv)
Other versions
FI118034B (fi
FI964004A0 (fi
Inventor
Wolfgang Muller
Thomas Stratz
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of FI964004A0 publication Critical patent/FI964004A0/fi
Publication of FI964004L publication Critical patent/FI964004L/fi
Application granted granted Critical
Publication of FI118034B publication Critical patent/FI118034B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI964004A 1994-04-07 1996-10-04 Serotoniiniantagonistien (5HT3) käyttö fibromyalgian hoitoon FI118034B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9406857 1994-04-07
GB9406857A GB9406857D0 (en) 1994-04-07 1994-04-07 Improvements in or relating to organic compounds
PCT/EP1995/001264 WO1995027490A1 (en) 1994-04-07 1995-04-06 Use of serotonin antagonists (5ht3) for treating fibromyalgia
EP9501264 1995-04-06

Publications (3)

Publication Number Publication Date
FI964004A0 FI964004A0 (fi) 1996-10-04
FI964004L true FI964004L (fi) 1996-11-29
FI118034B FI118034B (fi) 2007-06-15

Family

ID=10753131

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964004A FI118034B (fi) 1994-04-07 1996-10-04 Serotoniiniantagonistien (5HT3) käyttö fibromyalgian hoitoon

Country Status (22)

Country Link
US (2) US5773436A (fi)
EP (1) EP0804196B1 (fi)
JP (1) JP2818303B2 (fi)
KR (1) KR100415181B1 (fi)
CN (1) CN1084618C (fi)
AT (1) ATE225176T1 (fi)
AU (1) AU706279B2 (fi)
CA (1) CA2186844C (fi)
CZ (1) CZ290359B6 (fi)
DE (1) DE69528475T2 (fi)
DK (1) DK0804196T3 (fi)
ES (1) ES2184797T3 (fi)
FI (1) FI118034B (fi)
GB (1) GB9406857D0 (fi)
HU (1) HU226892B1 (fi)
MX (1) MX9604589A (fi)
NO (1) NO312745B1 (fi)
PL (1) PL316658A1 (fi)
PT (1) PT804196E (fi)
RU (1) RU2165760C2 (fi)
SK (1) SK281603B6 (fi)
WO (1) WO1995027490A1 (fi)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914322A1 (en) * 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
JP2002537255A (ja) 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
DE60042446D1 (de) * 1999-02-18 2009-08-06 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
GB9918425D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
WO2003029252A1 (en) 2001-10-02 2003-04-10 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
EP1476449A1 (en) 2002-02-19 2004-11-17 PHARMACIA & UPJOHN COMPANY Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
CA2476624A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
CA2499128C (en) * 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
MXPA05007379A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
KR20060120694A (ko) * 2003-12-22 2006-11-27 메모리 파마슈티칼스 코포레이션 인돌, 1ｈ-인다졸, 1,2-벤즈이속사졸 및1,2-벤즈이소티아졸, 및 이들의 제법 및 용도
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
BRPI0508771A (pt) 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
CA2567977A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
BRPI0510212A (pt) * 2004-05-07 2007-10-16 Memory Pharm Corp 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) * 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
MX2007007818A (es) * 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
MX2007007328A (es) * 2004-12-22 2007-07-25 Memory Pharm Corp Ligandos del receptor alfa-7 nicotinico y preparacion y sus usos.
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
EP3201203B1 (en) 2014-09-29 2021-05-19 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189002B1 (en) * 1984-12-20 1993-03-03 Sandoz Ag Treatment of gastrointestinal disorders using 5-ht3 antagonists
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB8623142D0 (en) * 1986-09-26 1986-10-29 Beecham Group Plc Compounds
US5246942A (en) * 1988-04-27 1993-09-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
US4963689A (en) * 1989-05-19 1990-10-16 Pfizer Inc. Heterocyclicguanidines as 5HT3 antagonists
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
RU2165760C2 (ru) 2001-04-27
SK281603B6 (sk) 2001-05-10
AU2305295A (en) 1995-10-30
US5985866A (en) 1999-11-16
DK0804196T3 (da) 2003-01-27
FI118034B (fi) 2007-06-15
AU706279B2 (en) 1999-06-10
ATE225176T1 (de) 2002-10-15
DE69528475T2 (de) 2003-02-20
FI964004A0 (fi) 1996-10-04
GB9406857D0 (en) 1994-06-01
CZ291596A3 (en) 1997-03-12
NO964236D0 (no) 1996-10-04
CA2186844A1 (en) 1995-10-19
NO312745B1 (no) 2002-07-01
US5773436A (en) 1998-06-30
HU226892B1 (en) 2010-01-28
CN1147767A (zh) 1997-04-16
SK127896A3 (en) 1997-12-10
CN1084618C (zh) 2002-05-15
JP2818303B2 (ja) 1998-10-30
NO964236L (no) 1996-10-04
WO1995027490A1 (en) 1995-10-19
EP0804196A1 (en) 1997-11-05
CZ290359B6 (cs) 2002-07-17
CA2186844C (en) 2007-01-09
HU9602721D0 (en) 1996-11-28
PL316658A1 (en) 1997-02-03
PT804196E (pt) 2003-01-31
MX9604589A (es) 1997-11-29
HUT74992A (en) 1997-03-28
KR100415181B1 (ko) 2004-07-30
ES2184797T3 (es) 2003-04-16
JPH09511739A (ja) 1997-11-25
DE69528475D1 (de) 2002-11-07
EP0804196B1 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
FI964004L (fi) Serotoniiniantagonistien (5HT3) käyttö fibromyalgian hoitoon
DK0738150T3 (da) Bicykliske fibrinogene antagonister
DE4290881T1 (de) Verfahren zur Massage der Wirbelsäulengegend
FI945441A7 (fi) Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmi stamiseksi
IT9021645A0 (it) Procedimento per il trattamento di torbide di raffineria
FI971527A7 (fi) Indolijohdannaisten käyttö erilaisten sairauksien hoitoon
FI963531A7 (fi) Kinoliini-3-karboksamidiyhdisteiden uusi käyttö
EE9600160A (et) Kinoliin-3-karboksamiidi ühendite kasutamine uuel otstarbel
FI913713A7 (fi) Uusia bisyklisiä aminosubstituoituja yhdisteitä
ITMI941043A0 (it) Apparecchiatura per la realizzazione di tracheostoria translaringea
NO970126D0 (no) Anvendelse av benzaldhyder for markering av hydrokarboner
KR950700739A (ko) β-카르볼린의 새로운 용도(New Use of β-Carbolines)
MX9100630A (es) Empleo de compuestos de molibdeno para la coagulacion de pinturas
FI964410A7 (fi) Menetelmä 4-amino-delta4-3-ketosteroidien valmistamiseksi 4-nitro-delt a4-3-ketosteroidien kautta
FI915785L (fi) Menetelmä 3-asemassa substituoitujen tiofeenien valmistamiseksi
FI904570A7 (fi) Menetelmä uusien alkanofenonien valmistamiseksi I
NO920983D0 (no) Fremgangsmaate for behandling av nevrodegenerative tilstander
FI971177L (fi) Bisyklisiä karboksiamideja 5-HT1A-antagonisteina
IT1241025B (it) Procedimento per la purificazione di bagni di nichelatura.
FI972035L (fi) Hydraatti lääketieteellistä käyttöä varten
KR890701106A (ko) 과지혈증의 치료를 위한 옥소퀴나졸린 유도체의 용도
MX9200764A (es) Procedimiento para la preparacion de 3-hidroxipropanonitrilos 3-substituidos.
MX9100857A (es) Procedimiento para la purificacion de 4-acetoxiestireno
FI951441A7 (fi) Menetelmä 5-formyyliamino-pyrimidiinien valmistamiseksi
MX9200765A (es) Procedimiento para la preparacion de 3-hidroxipropanonitrilos 3-substituidos.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

PC Transfer of assignment of patent

Owner name: NOVASEARCH AG

Free format text: NOVASEARCH AG

FG Patent granted

Ref document number: 118034

Country of ref document: FI

MM Patent lapsed